In the present study, we used the specific GPR44 antagonist AZ8154 to investigate the role of GPR44 in the function and survival rate of human islets exposed to a type 1 diabetes-like milieu both in vitro (mimicked by islet exposure to high concentration of glucose [HG] and to IL-1β) and in vivo (using human islets transplanted to a diabetic immunodeficient mouse model). Here, PTGDR2 is linked to type 1 diabetes mellitus.